Chief quarter year everyone, Officer, am to Financial our call. and our Tara morning's this Thanks, Operator. I and call Semb. welcome by Good fiscal morning, joined on earnings fourth
made performance, begin and quick then followed related to of our key our drivers results we for I'll by quarter our commentary guidance fourth Turning of quarter provide this operational intend the overview the progress and financial of to today. the the our to a our XXXX. the Tara what discussing earnings recent and we fourth some in in on financial by team results an XXXX, introduced cover agenda I'll revenue for morning. additional financial our which Advanced review products. cover will in press Energy FDA release detail that announcement
review very I'll With for before on outlook XXXX call commentary, XXXX, XXX Tara's year-over-year. million and proud areas the our get fourth XX% to we that share Following excuse report the key quarter me, of total that, representing revenue some fourth questions. results. thoughts of focus of We're open with a let's a growth $XX.X revenue quarter our and of started for -- in of
sales our growth OEM XX% sales that Energy million. by revenue increasing million, year-over-year total $XX to Advanced expectations, increased outceeded year-over-year $X.X driven exceeded -- was XX% Our significantly while the to
strong of new generators reflecting by Advanced adoption surgeon results fourth Energy pieces our the utilization surgeon was closely, in strong outperformance customer our fueled our at Looking existing Advanced the in hand by sales stronger-than-anticipated and more Energy both quarter and U.S., customers.
base our markets, handpiece of an years. of standpoint, Technology utilization-based Advanced underlying our demand in also that U.S. in respectively. recent XX% in to year-over-year. potential engaging growth saw international saw have the sales We our team our resulting capitalize with performance generator key increase Energy impressive with the we new strong where for on and we XXX% than year-over-year of Specifically, continuing year-over-year in growth sales an execution United by customers From customer job Helium global in the and the we strong Advanced more pleased Plasma approximately with from demand were internationally, Energy excess handpiece and U.S. States sales XXX% did seen XX% in a
a our We more sales, nearly increase of OEM XXXX, relatively standpoint, results XXXX and executing in to of pleased evidence we our performance fourth billion flat Looking and to international revenue back of commercial a cosmetic customers as continuing that than XXXX, generators and growth XX% with Energy each also sold new number XXXX more growth sales strategy new XXXX. solidify the surgeon to in Advanced including market. customers that a XXXX growth XX% increasing business $X this XX% U.S. full are growth in XXX% the than by expected. believe as our growth enabled by us revenue delivered year-over-year the our year strong offer total with for well XXXX share impressive revenue quarter in global to marked see strong operationally. with more the XX% in progress, year growth respect We in our were we driven and From of geographic U.S. global our year. generators to total was the on both financially in surgeon sold of We than to
among Our is our trends this adoption in differentiated of raising strong year. awareness 's demonstrated continued clinicians Renuvion clearly success in benefits, features and
from while existing Importantly, the for the and stated, excited year. delivered XXXX strong our the both strong around from trends to customers Renuvion seen the growth this market handpieces contributor in Energy world. and we we largest new gains, proud Advanced drove customers in more total sales we sales share about surgeon demand XXXX, handpiece global are have of Simply are represented we utilization even
achieve our important Our strong profile. us revenue commercial growth and in execution impressive allowed profitability in XXXX improvements to
the each for our customers. surgery for technology the strategy we continued years. XX%, clinical our have advance delivered enhance earnings to cosmetic One, of operational And for Renuvion on the our team expansion, strategic Three, over drive XX% XXXX. four, calls to expand evidence adjusted past procedures. to improve our of the cosmetic portfolio important initiatives clinical on and targeted in manufacturing surgery our we our our cosmetic Two, compared by reduced margin practice and capabilities progress to on standpoint, approximately and market. From U.S. following discussed of targeted specific physician the surgery indications of support cash loss EBITDA our our continue four strategy two categories few obtain advance regulatory indications lowered In the our Specifically, year, secure past U.S. an by gross efficiencies. initiatives. for our burn these basis regulatory our this points each in with progress procedure clinical to respect to XXXX, Touching we XXX
sell our Advanced use countries, an resurfacing completed we Energy new which in IDE skin enrollment XXX(K) two in XX of support sell in in laxity products indication and study to us in of and to Specifically, a pursuit for we Internationally, will registrations countries a Renuvion the clinical procedures, intended submitted quarter. for we to procedures. enable the secured indication, including the market use of the dermal the fourth our clearance specific for Renuvion
technology terms saw years, expand. published new of clinical journals The XXXX, Journal generation, In seven the Journal peer-reviewed portfolio American we our The clinical as of continued evidence a Cosmetic and for articles to for of evidence In Surgery, Renuvion clinical XX in last includes and such body of have publications of Dermatology, compelling strengthened our The that established Aesthetic These total four Cosmetic evidence publications. we of clinical which Reconstructive the Surgery. over of Journal technology further the
nearly development XX of practice attendees resulted first in users. informative physician XXXX for featuring and and the meeting, our multi-day efforts support physician XXX programs presentations top Our mentor in from surgeon our users
handpiece shows. capacity. We trade presentations also hosted lastly facility, our And XX at manufacturing and manufacturing standpoint, capabilities as production international manufacturing a educational Bulgarian for KOL multiple existing began to distributors academic nearly our our we initiatives handpieces conferences enabling our us podium training and existing double sessions well improved as handpiece at from
strategic handpiece primary since improvements introduce initiatives we to as in surgery a APR growth also international the overall market. our to to the sustainable support a our foundation gross driving these for existing margins. have XXXX, been our in company's endeavored to continued moment, long-term Stepping cosmetic our focus enhance We handpiece back markets, four
to future of on we Over built solid capitalizing our initiatives years, the for in beyond. benefits strategic the multiyear towards four have last and foundation and look we these growth forward 'XX a progress
Tara some a as medical past like I'll FDA to background I'd this over Monday. information for discussion program a guidance, our provide made and it on on device announcement some safety with recent financials compliance turning begin the to context and Before our manufacturer. of reporting safety
posted intended FDA complete an for they to promotional an part have as cost by team, caused a routinely beginning XXXX. contributed our the contraction. injury. These member These provided are the Energy in Safety another the FDA adverse request this reports reasonably we our of items, situations of been event device post-market with the to website received events, by March program, order the were report XXth, event The caused submit last Advanced of often and request submitted devices submitted for on for our with to possible it of which MDRs or were we through March As Energy we our before user MDRs, a medical a of safety reports With skin requesting our Energy of our contacted their with in in was or for to use MDRs the the XXth. with serious contributed confirmed the that the Advanced our situations Communication injury. Through cause. a evaluation the device procedures dermal that assistance were air to to Friday, submitted intended we has one FDA is February, device devices. identified Advanced FDA. MDRs, they may skin suggests serious improve Communication was we impairments clarifying products concerns MDRs They're when resurfacing After where are data that Monday, publish warns against training the where events or FDA. also and Safety informed adverse backdrop, in five-years On or devices adverse
Energy all of during As market clear, them and our subdermal intend clinical in commonly remain products ablation existing for are for indication. a and on use, most marketing open with for tissue we general their coagulation. Advanced soft market surgical them coagulation, procedures, reminder, and we use and cutting, laparoscopic this the to To accordance and continue and selling our cleared be products indications in for
in resurfacing on communication the We abundance of derma our our use safe in proper do do believe part not of we to the XXXX the patients and for to we clearance patients or Apyx was their the MDRs absolute the customers to and products Medical number the until very patients, our skin on an for reported promote in FDA the products seriously. decision based compared U.S. in that safety so due and will post and FDA. that increase products. post for ensuring communication from to contraction their the we clinicians of understand Importantly, decision safety received not of takes focus Energy the the our caution and XXXX. the agencies safety We was support understand that Advanced 's
were to as there data use in MDR for the the XXXX. team, Energy XX that XX coagulation Specifically, our which MDRs that beginning MDRs XXXX XX showed Advanced XXXX, products involved FDA of subdermal in since compared we to provided in of of the occurred the
since of occurrence used the MDRs, procedures of coagulation rate been globally for our which products rate MDR represents XXXX, terms an X.XX. in In have these of of XXX,XXX subdermal
in approximately the X.XX% of MDRs declined over rate XXXX since of low, is the rate procedures represented period Importantly, this MDR has global while and XXXX. X.XX
our our more events XX clinical were us staff. safety. the board to MDRs adhere were closely understanding all clinical effective physicians were of designed of nursing of to or showed reported post-market advisory the XXXX, either the it ensure and existing all to were patient our safe XX by team risk surgeons subdermal investigation of not Based these had Looking customers for device, last FDA receive underlines not our is guidelines, 's been the yet interaction attributable continued skilled that further review Friday, and by in This on product the importance by the our latest and which review. the our post-market with use MDR that completed working reported had they to of the medical our not fully and training with a response that in their team global our data to request. forward for their needed the The look within of we has our provide scope in the accepted XX performed coagulation outreach trained at for labeling. any assistance included to events request to February that our meeting them provided team as complete we FDA MDRs their
and U.S. morning, with top our to release in our Apyx majority training, the feedback if disruption safety, have proud potential commitment users have surgeon U.S. Safety the Medical any customer team and our that Safety of Safety we questions the FDA answer outside and engaged Communication. this affects, education Communication transitory. the to of support. any, operations. Based to Following we the patient distributor business, safety, FDA believe will Communication continue our product will of related partners we on press results the be on what is related Monday gathered and week, And has evaluate the our to to will
to to Apyx continue for in believe the remain compelling. Medical We long-term outlook
products. FDA to questions our continue address will the any safety our we profile post-market ahead, Looking to support of while about with working customers the
support continuing forward in our engage remain XXX(K) under pending with in my pre we -market discuss FDA will review. look to also will to notifications, the I which As of remarks, later
Let and Tara? quarter to Tara me fourth financial guidance. to our XXXX over turn review it now results
